



**Supplementary Figure S6. Effects of 17-AAG and ganetespib on cell viability and mutant ERBB2 expression in ERBB2-dependent Ba/F3 cells.** (Left) Ba/F3 cells, transformed to IL-3 independence by ectopic expression of ERBB2 harboring YVMA exon 20 insertion mutation, were treated with 17-AAG or ganetespib at the indicated concentrations for 72 hours and cell viability assessed, demonstrating the greater potency of ganetespib. (Right) Western blot demonstrating the depletion of the mutant ERBB2 protein after exposure to the indicated concentrations of 17-AAG or ganetespib.